Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jun;25(6):689–694. doi: 10.1111/j.1365-2125.1988.tb05254.x

Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure.

A C Tweddel 1, W Martin 1, A I McGhie 1, I Hutton 1
PMCID: PMC1386445  PMID: 3203040

Abstract

1. The efficacy of felodipine a new calcium channel blocker with selective vasodilator activity in the management of severe low output cardiac failure, secondary to coronary heart disease, was determined in 10 patients. 2. Haemodynamic measurements were made at rest and during dynamic exercise and left ventricular function was assessed by radionuclide ventriculography. 3. Significant increases in cardiac index, stroke volume index and ejection fraction were found particularly during exercise, both acutely and following 4 weeks administration of felodipine therapy. 4. Felodipine could well have a significant role in the long term management of the patient with chronic cardiac failure.

Full text

PDF
689

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 1982 Dec 23;307(26):1618–1627. doi: 10.1056/NEJM198212233072605. [DOI] [PubMed] [Google Scholar]
  2. Brooks N., Cattell M., Pidgeon J., Balcon R. Unpredictable response to nifedipine in severe cardiac failure. Br Med J. 1980 Nov 15;281(6251):1324–1324. doi: 10.1136/bmj.281.6251.1324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cleland J. G., Dargie H. J., McAlpine H., Ball S. G., Morton J. J., Robertson J. I., Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) 1985 Nov 9;291(6505):1309–1312. doi: 10.1136/bmj.291.6505.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Johnsson G., Murray G., Tweddel A., Hutton I. Haemodynamic effects of a new vasodilator drug, felodipine, in healthy subjects. Eur J Clin Pharmacol. 1983;24(1):49–53. doi: 10.1007/BF00613926. [DOI] [PubMed] [Google Scholar]
  5. LEWIS B. M., HOUSSAY H. E., HAYNES F. W., DEXTER L. The dynamics of both right and left ventricles at rest and during exercise in patients with heart failure. Circ Res. 1953 Jul;1(4):312–320. [PubMed] [Google Scholar]
  6. McGhie I., Martin W., Tweddel A., Hutton I. The detection of coronary artery disease: a comparison of exercise thallium imaging and exercise equilibrium radionuclide ventriculography. Eur J Nucl Med. 1987;13(1):18–23. doi: 10.1007/BF00252640. [DOI] [PubMed] [Google Scholar]
  7. Muir A. L., Wathen C. G., Hannan W. J. Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension. Drugs. 1985;29 (Suppl 2):59–65. doi: 10.2165/00003495-198500292-00012. [DOI] [PubMed] [Google Scholar]
  8. Packer M., Frishman W. H. Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective. Am J Cardiol. 1982 Oct;50(4):881–885. doi: 10.1016/0002-9149(82)91249-8. [DOI] [PubMed] [Google Scholar]
  9. Packer M., Meller J., Gorlin R., Herman M. V. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979 Mar;59(3):531–539. doi: 10.1161/01.cir.59.3.531. [DOI] [PubMed] [Google Scholar]
  10. Packer M. Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol. 1983 Nov;2(5):841–852. doi: 10.1016/s0735-1097(83)80230-7. [DOI] [PubMed] [Google Scholar]
  11. Robinson B. F., Dobbs R. J., Kelsey C. R. Effects of nifedipine on resistance vessels, arteries and veins in man. Br J Clin Pharmacol. 1980 Nov;10(5):433–438. doi: 10.1111/j.1365-2125.1980.tb01784.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Romankiewicz J. A., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs. 1983 Jan;25(1):6–40. doi: 10.2165/00003495-198325010-00002. [DOI] [PubMed] [Google Scholar]
  13. Timmis A. D., Campbell S., Monaghan M. J., Walker L., Jewitt D. E. Acute haemodynamic and metabolic effects of felodipine in congestive heart failure. Br Heart J. 1984 Apr;51(4):445–451. doi: 10.1136/hrt.51.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Timmis A. D., Smyth P., Kenny J. F., Campbell S., Jewitt D. E. Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure. Br Heart J. 1984 Sep;52(3):314–320. doi: 10.1136/hrt.52.3.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tweddel A. C., Hutton I. Felodipine in ventricular dysfunction. Eur Heart J. 1986 Jan;7(1):54–60. doi: 10.1093/oxfordjournals.eurheartj.a061958. [DOI] [PubMed] [Google Scholar]
  16. Tweddel A. C., Johnsson G., Pringle T. H., Murray R. G., Hutton I. The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease. Eur Heart J. 1983 Oct;4(10):699–705. doi: 10.1093/oxfordjournals.eurheartj.a061381. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES